Simulations Plus

Activity Seen Against Both Drug-Sensitive and Drug-Resistant Strains

Net sales increase 6.4% to record for any quarter of $2.789 million; first half net income up 22.7% to $1.810 million

Conference Call to Be on Tuesday, April 10, at 4:15 PM ET

New Molecule Has Excellent Activity Against Malaria Parasite

Company Now Owns IP in ADMET Predictor™ Enslein Metabolism Module

Net sales increase to new record for any quarter of $2.789 million, up 24% sequentially and 6.4% compared to 2QFY11

Dr. David Ralph, Professor of Marketing at Pepperdine University, to Replace Dr. Richard Weiss, Retiring after Nearly 15 Years on Board

Board of directors declares an ongoing quarterly dividend of $0.05 per share

Net sales increase 9.6% to first quarter record $2.248 million; Net income up 30.9% to $755,000

Conference Call to be on Wednesday, January 18, at 4:15 PM ET

Fiscal Year Pharmaceutical Software and Services Up 14.7%, EPS Up 29.3%

Conference Call to be on Thursday, December 1, 2011 at 4:30 PM EST

Prentke Romich Company to Acquire Subsidiary and Continue Operations

Company Uses Proprietary Software Tools to Design New Drug-like Molecules for Resistant Malaria Parasite

Pharmaceutical Software and Services Revenues Increase 6.9% for 4th Quarter, up 14.7% for the Fiscal Year

In-house Design Widens Eye Gaze Offerings and Substantially Increases Margins

Record Quarterly Revenue of $3.44 Million; Consolidated Earnings Up 42% and EPS Up 49% from 3QFY10